9月3日艾伯维宣布艾可瑞妥单抗(epcoritamab)已纳入国家药品监督管理局药品审评中心优先审评品种名单。该药物用于治疗复发或难治性滤泡性淋巴瘤(FL)成人患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.